Connect Sign In
CYP2C19
Ordering Recommendation
Assesses genetic risk of abnormal drug metabolism for CYP2C19 substrates. May aid in drug selection and dose planning for drugs metabolized by CYP2C19.
New York DOH Approval Status
Specimen Required
Lavender (EDTA), Pink (K2EDTA), or Yellow (ACD Solution A or B).
Transport 3 mL whole blood. (Min: 1 mL)
Refrigerated.
Plasma or serum. Specimens collected in sodium heparin or lithium heparin. Frozen specimens in glass collection tubes.
Ambient: 72 hours; Refrigerated: 1 week; Frozen: 1 month
Methodology
Polymerase Chain Reaction (PCR)/Fluorescence Monitoring
Performed
Varies
Reported
5-10 days
Reference Interval
By report
Interpretive Data
Refer to report
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Couseling and informed consent are recommended for genetic testing. Consent forms are available online.
Laboratory Developed Test (LDT)
Note
Whole blood is the preferred specimen. Saliva samples that yield inadequate DNA quality and/or quantity will be reported as inconclusive if test performance does not meet laboratory-determined criteria for reporting.
Hotline History
Hotline History
CPT Codes
81225
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 2008936 | CYP2C19 Phenotype | 79714-2 |
| 3001509 | 2C19GENO Specimen | 31208-2 |
| 3001510 | CYP2C19 Genotype | 57132-3 |
| 3001511 | 2C19GENO Interpretation | 50398-7 |
| 3016869 | EER CYP2C19 | 11526-1 |
Aliases
- 2C19
- amitriptyline
- antidepressants
- clomipramine
- clopidogrel
- CYP2C19
- Cytochrome P450 2C19 Genotype
- dexlansoprazole
- doxepine
- escitalopram
- imipramine
- lansoprazole
- omeprazole
- pantoprazole
- Plavix
- PPIs
- protein pump inhibitors
- rabeprazole
- sertraline
- SSRI
- TCA
- trimipramine
- voriconazole
